<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243565</url>
  </required_header>
  <id_info>
    <org_study_id>17-AKD-2</org_study_id>
    <nct_id>NCT03243565</nct_id>
  </id_info>
  <brief_title>Effect of OM-85 on Respiratory Tract Infections and Adenoid Tissue in Children With Adenoid Hypertrophy</brief_title>
  <official_title>Effect of VaxoralÂ® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Sami Ulus Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical research question: Can OM-85 reduce the recurrence of respiratory tract infections&#xD;
      (RTIs) in children with AH by stimulating the immunological response of the host and&#xD;
      therefore, as a consequence reduce the size of adenoid tissue in children with adenoid&#xD;
      hypertrophy? Can this prevent further complications such as surgery need? Half of&#xD;
      participants will receive OM-85, while other half will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OM-85 significantly reduces RTIs in children. This effect was proved by many clinical studies&#xD;
      and meta-analyses. A Cochrane meta-analysis first published in 2006 and updated recently&#xD;
      (Del-Rio-Navarro 2012) showed that immunostimulants (IS) could reduce acute RTIs (ARTIs) by&#xD;
      almost 39% when compared to placebo. Among the different IS, OM-85 showed the most robust&#xD;
      evidence with 4 trials of &quot;A quality&quot; according to the Cochrane grading criteria. Pooling six&#xD;
      OM-85 studies, the Cochrane review reported a mean number of ARTIs reduction by -1.20 [95%&#xD;
      Confidence Interval (CI): -1.75, -0.66 ] and a percentage difference in ARTIs by -35.9% [95%&#xD;
      CI: -49.46, -22.35 ] compared to placebo.&#xD;
&#xD;
      Adenoid hypertrophy (AH) is one of the most important respiratory disease in preschool&#xD;
      children. In normal conditions adenoid tissue enlarges up to 5 years and become smaller&#xD;
      afterwards. But in some children who have recurrent upper respiratory tract infections&#xD;
      (URTI)s, it keeps growing and this can be associated with complications. AH may cause&#xD;
      recurrent respiratory infections and each infection contribute to enlargement of adenoid&#xD;
      tissue thus promoting a vicious cycle. Additionally enlarged adenoids are known to be&#xD;
      reservoir for microbes and cause of recurrent or long lasting RTIs.&#xD;
&#xD;
      AH is associated with chronic cough, recurrent and chronic sinusitis, recurrent tonsillitis,&#xD;
      recurrent otitis media with effusion, recurrent other respiratory problems such as, nasal&#xD;
      obstruction and sleep disturbances, sleep apneas. Eventually, AH causes loss of appetite and&#xD;
      growth delay; it is often associated with misusing or over use of antibiotics and often&#xD;
      eventually requires surgery. It decreases quality of life both in children and parents and it&#xD;
      represents a burden not only for families but also for health care system and society due to&#xD;
      increased health cost4.&#xD;
&#xD;
      In one study which investigated the structural and immunological aspects of tonsils and&#xD;
      adenoids of 105 children (54 males and 51 females, aged between 4 and 18 years) who were&#xD;
      affected by chronic inflammatory hypertrophy of palatine tonsils and adenoids which had not&#xD;
      responded to previous medical treatments and who underwent adenotonsillectomy because of&#xD;
      recurrent inflammatory episodes with fever, it was demonstrated that deficit in the&#xD;
      activa-tion of the immune system could be represented by the small quan-tity of messenger&#xD;
      ribonucleic acid (mRNA)s for interleukin-2 (IL-2) and interleukin-4 (IL-4) detected in our&#xD;
      population, suggesting a defective activation of Th1 and Th2 lymphocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomised, double-blind, placebo-controlled, parallel group, phase IV study. First group will receive OM-85 (first 10 day consecutive 3 months; standard treatment regimen) Second group will receive matching placebo at the same posology (first 10 day consecutive 3 months).&#xD;
A second cure of treatment will be given 6 months after inclusion. Patients will be recruited from 01 August 2017 to 01 February 2018. The trial will begin in August 2017 and will be completed in February 2019.&#xD;
By this way every patient will be studied over all seasons (1 year study) .</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization will be done by throwing the coin. Family of patients and doctor (Coordinator / Responsible Investigator Serap Ozmen and Associate Investigator Soner Sahin) will be blind; Researcher Ilknur Bostanci and assistant researcher Gulay Senel will appoint drugs and placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of number of respiratory tract infections (RTIs)</measure>
    <time_frame>within 12 months</time_frame>
    <description>number of respiratory tract infections (RTIs) such as adenoiditis, sinusitis, tonsillitis, otitis, bronchitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in duration of RTIs</measure>
    <time_frame>within 12 months</time_frame>
    <description>duration of RTIs (day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of antibiotic use</measure>
    <time_frame>within 12 months</time_frame>
    <description>number of antibiotic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of missed school days</measure>
    <time_frame>within 12 months</time_frame>
    <description>missed school days (day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of surgery need</measure>
    <time_frame>within 12 months</time_frame>
    <description>Whether or not surgery (adenoidectomy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoid and tonsil survey</measure>
    <time_frame>within 12 months</time_frame>
    <description>before and after the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of adenoid tissue over the 12 months according to radiographic and flexible nasopharyngoscopic evaluation</measure>
    <time_frame>1 year</time_frame>
    <description>The data will be recorded as a perceived percent obstruction of the choana by the adenoid pad, as seen through the endoscope; Lateral neck radiographs will taken and interpreted by the method of Cohen and Konak by a blinded radiologist (Cohen D, Konak S. The evaluation of radiographs of the nasopharynx. Clin Otolaryngol 1985; 10: 73-8.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Adenoid Hypertrophy</condition>
  <condition>Adenoid Hyperplasia</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Preschool Children</condition>
  <arm_group>
    <arm_group_label>OM-85</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OM-85</intervention_name>
    <description>OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.</description>
    <arm_group_label>OM-85</arm_group_label>
    <other_name>Vaxoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children (age: 2-6 years)&#xD;
&#xD;
          -  Who experienced recurrent RTIs (at least 3 episodes in 6 months before the inclusion)&#xD;
&#xD;
          -  Who have symptoms of AH (snoring; mouth breathing awake; mouth breathing asleep; nasal&#xD;
             congestion; hyponasal voice; chronic nasal discharge; daytime drowsiness, or&#xD;
             hyperactivity; restless sleep; sleep apnoea &lt;15 sec; night cough; and poor oral&#xD;
             intake/weight loss) based on the symptoms score questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atopy&#xD;
&#xD;
          -  Gastroesophageal reflux&#xD;
&#xD;
          -  Immune deficiency&#xD;
&#xD;
          -  Asthma or allergic rhinitis&#xD;
&#xD;
          -  Premature delivery&#xD;
&#xD;
          -  Anatomic alterations of the respiratory tract; chronic respiratory diseases&#xD;
             (tuberculosis and cystic fibrosis); autoimmune disease; liver&#xD;
&#xD;
          -  Kidney failure; malnutrition; cancer&#xD;
&#xD;
          -  Treatment with inhaled or systemic corticosteroids within the previous month&#xD;
&#xD;
          -  Treatment with immunosuppressants, immunostimulants, gamma globulins, or&#xD;
             anticonvulsive drugs within the previous 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serap Ozmen</last_name>
    <role>Study Chair</role>
    <affiliation>Health of Science University, Dr Sami Ulus Maternity and Children Research and Training Hospital, Ankara, TURKEY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serap Ozmen, MD</last_name>
    <phone>+903123056250</phone>
    <email>serapozmen@yahoo.com</email>
  </overall_contact>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Sami Ulus Children's Hospital</investigator_affiliation>
    <investigator_full_name>Serap Ozmen</investigator_full_name>
    <investigator_title>MD, Pediatric Allergist and Assoc. Prof of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>adenoid hypertrophy</keyword>
  <keyword>Adenoid Hyperplasia</keyword>
  <keyword>children</keyword>
  <keyword>respiratory tract infection</keyword>
  <keyword>adenotonsillectomy</keyword>
  <keyword>OM-85</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan: SAP OM85adenoid</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03243565/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: ICF OM85adenoid</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03243565/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: SP OM85adenoid</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03243565/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: SUM OM85adenoid</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03243565/Prot_SAP_ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

